These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. High-turnover osteoporosis and diffuse idiopathic skeletal hyperostosis induced by retinoid therapy in a patient with superficial bladder cancer. Theiler R; Kränzlin M; Zynamon A; Tyndall A; Schmid HP Br J Urol; 1995 Sep; 76(3):400-1. PubMed ID: 7551859 [No Abstract] [Full Text] [Related]
25. Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature. Halverstam CP; Zeichner J; Lebwohl M J Cutan Med Surg; 2006; 10(6):291-9. PubMed ID: 17241599 [TBL] [Abstract][Full Text] [Related]
26. [Unwanted bone changes in systemic treatment with synthetic retinoids]. Melnik B; Plewig G Hautarzt; 1987 Apr; 38(4):193-7. PubMed ID: 3474220 [TBL] [Abstract][Full Text] [Related]
27. [Rheumatologic effects of etretinate]. Cuny JF; Schmutz JL; Terver MN; Aussedat R; Cointin M; Weber M; Beurey J Ann Dermatol Venereol; 1989; 116(2):95-102. PubMed ID: 2660711 [TBL] [Abstract][Full Text] [Related]
28. Synthetic retinoids in dermatology. Heller EH; Shiffman NJ Can Med Assoc J; 1985 May; 132(10):1129-36. PubMed ID: 3158386 [TBL] [Abstract][Full Text] [Related]
29. [Oral treatment with retinoids-mechanisms of action and clinical experiences in erythematosquamous and other dermatoses]. Hoting E; Maurach R; Meigel W Z Hautkr; 1982 Aug; 57(15):1137-43. PubMed ID: 6214899 [TBL] [Abstract][Full Text] [Related]
30. Differential hepatotoxicity of two oral retinoids (etretinate and isotretinoin) in a patient with palmoplantar psoriasis. Vahlquist A; Lööf L; Nordlinder H; Rollman O; Vahlquist C Acta Derm Venereol; 1985; 65(4):359-62. PubMed ID: 2413699 [TBL] [Abstract][Full Text] [Related]
31. Systemic retinoids in dermatology. Dicken CH; Connolly SM Mayo Clin Proc; 1982 Jan; 57(1):51-7. PubMed ID: 6172678 [TBL] [Abstract][Full Text] [Related]
32. Cortical hyperostosis and enthesopathy due to long-term etretinate administration. Guit GL; Obermann WR; van der Schroeff JG; Sillevis-Smitt HJ Diagn Imaging Clin Med; 1986; 55(4-5):214-8. PubMed ID: 3095013 [TBL] [Abstract][Full Text] [Related]
34. A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. Vahlquist C; Michaëlsson G; Vahlquist A; Vessby B Br J Dermatol; 1985 Jan; 112(1):69-76. PubMed ID: 3882125 [TBL] [Abstract][Full Text] [Related]
35. The spectrum of skeletal changes associated with long-term administration of 13-cis-retinoic acid. Lawson JP; McGuire J Skeletal Radiol; 1987; 16(2):91-7. PubMed ID: 3107131 [TBL] [Abstract][Full Text] [Related]
37. A retrospective study of bone changes in adults treated with etretinate. Halkier-Sørensen L; Andresen J J Am Acad Dermatol; 1989 Jan; 20(1):83-7. PubMed ID: 2913084 [TBL] [Abstract][Full Text] [Related]
38. [Retinoids and congenital malformations]. van der Schroeff JG Ned Tijdschr Geneeskd; 1986 Apr; 130(14):622-3. PubMed ID: 3458029 [No Abstract] [Full Text] [Related]
39. [Retinoid treatment of pediatric skin diseases]. Kuokkanen K Duodecim; 1989; 105(8):772-7. PubMed ID: 2721405 [No Abstract] [Full Text] [Related]
40. [Manifestations of diffuse idiopathic skeletal hyperostosis on the forefoot]. Fischer E Rofo; 1987 Nov; 147(5):532-6. PubMed ID: 2825289 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]